[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555830":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":22,"locations":28,"responsibleParty":142,"collaborators":145,"id":157,"slug":158,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":10,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":165,"minAge":166,"maxAge":10,"enrollmentInfo":167,"targetDuration":170,"studyType":171,"phases":10,"briefSummary":172,"conditions":173,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":185},{"fullName":5,"class":6},"Northwestern University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"HFpEF",null,"Participants with HFpEF",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-HFpEF","Participants without HFpEF",[16,19],{"name":17,"affiliation":5,"role":18},"Sanjiv Shah, MD","PRINCIPAL_INVESTIGATOR",{"name":20,"affiliation":21,"role":18},"Margaret Redfield, MD","Mayo Clinic",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Laura Alagna","CONTACT","312-695-6765","heartsharestudy@northwestern.edu",[29,49,68,91,108,126],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Chicago","Illinois","60611","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-87.65005,41.85003,{"lat":40,"lon":39},[43,45,47],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":44},"laura.alagna@northwestern.edu",{"name":46,"role":18,"phone":10,"phoneExt":10,"email":10},"Sadiya Khan, MD",{"name":48,"role":18,"phone":10,"phoneExt":10,"email":10},"Laura Rasussen-Torvik, PhD, MPH",{"facility":50,"status":30,"city":51,"state":52,"zip":53,"country":34,"countryCode":35,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Johns Hopkins University","Baltimore","Maryland","21287",{"type":37,"coordinates":55},[56,57],-76.61219,39.29038,{"lat":57,"lon":56},[60,63,65],{"name":61,"role":25,"phone":10,"phoneExt":10,"email":62},"Matt Kauffman","mkkauffman@jhmi.edu",{"name":64,"role":18,"phone":10,"phoneExt":10,"email":10},"Kavita Sharma, MD",{"name":66,"role":67,"phone":10,"phoneExt":10,"email":10},"David Kass, MD","SUB_INVESTIGATOR",{"facility":69,"status":30,"city":70,"state":71,"zip":72,"country":34,"countryCode":35,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Mass General Brigham","Boston","Massachusetts","02114",{"type":37,"coordinates":74},[75,76],-71.05977,42.35843,{"lat":76,"lon":75},[79,83,85,87,89],{"name":80,"role":25,"phone":81,"phoneExt":10,"email":82},"Diane Cocca-Spofford","617-726-8228","dcoccaspofford@mgh.harvard.edu",{"name":84,"role":18,"phone":10,"phoneExt":10,"email":10},"Greg Lewis, MD",{"name":86,"role":67,"phone":10,"phoneExt":10,"email":10},"Akshay Desai, MD, MPH",{"name":88,"role":67,"phone":10,"phoneExt":10,"email":10},"Michael Givertz, MD",{"name":90,"role":67,"phone":10,"phoneExt":10,"email":10},"Scott Solomon, MD",{"facility":21,"status":30,"city":92,"state":93,"zip":94,"country":34,"countryCode":35,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Rochester","Minnesota","55905",{"type":37,"coordinates":96},[97,98],-92.4699,44.02163,{"lat":98,"lon":97},[101,105,106],{"name":102,"role":25,"phone":103,"phoneExt":10,"email":104},"Brendon Urena","507-538-8305","urena.brendon@mayo.edu",{"name":20,"role":18,"phone":10,"phoneExt":10,"email":10},{"name":107,"role":67,"phone":10,"phoneExt":10,"email":10},"Borlaug Barry, MD",{"facility":109,"status":30,"city":110,"state":111,"zip":112,"country":34,"countryCode":35,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Wake Forest University","Winston-Salem","North Carolina","27157",{"type":37,"coordinates":114},[115,116],-80.24422,36.09986,{"lat":116,"lon":115},[119,122,124],{"name":120,"role":25,"phone":121,"phoneExt":10,"email":10},"Ben Nelson","336-716-6789",{"name":123,"role":18,"phone":10,"phoneExt":10,"email":10},"Dalane Kitzman, MD",{"name":125,"role":67,"phone":10,"phoneExt":10,"email":10},"Alain Bertoni, MD, MPH",{"facility":127,"status":30,"city":128,"state":129,"zip":130,"country":34,"countryCode":35,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":37,"coordinates":132},[133,134],-75.16362,39.95238,{"lat":134,"lon":133},[137,140],{"name":138,"role":25,"phone":139,"phoneExt":10,"email":10},"Tiffany Sharkoski","215-615-2354",{"name":141,"role":18,"phone":10,"phoneExt":10,"email":10},"Julio Chirinos, MD, PhD",{"type":18,"investigatorFullName":143,"investigatorTitle":144,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sanjiv Shah","Stone Endowed Professor of Medicine, Director of Research, Bluhm Cardiovascular Institute, Principal Investigator, HeartShare Data Translation Center",[146,149,151,153,154,156],{"name":147,"class":148},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"name":150,"class":6},"Massachusetts General Hospital",{"name":152,"class":6},"Brigham and Women's Hospital",{"name":21,"class":6},{"name":155,"class":6},"Wake Forest University Health Sciences",{"name":127,"class":6},"100555830","myocardial-mechanisms-in-heart-failure-with-preserved-ejection-fraction-100555830",false,"NCT06517186","Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction","Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction (MM-HFpEF) A HeartShare Clinical Study","Inclusion Criteria:\n\n* HFpEF criteria\n\n  1. Age ≥30 years.\n  2. Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability)\n  3. Definition of HFpEF: signs and\u002For symptoms of HF, NYHA functional class II-IV, and at least one of the following:\n\n     1. Elevated BNP (≥75 pg\u002Fml in sinus rhythm or ≥225 pg\u002Fml in atrial fibrillation\u002Fflutter) or NTproBNP (≥225 pg\u002Fml in sinus rhythm or ≥675 in atrial fibrillation\u002Fflutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.\n     2. Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels \\[using the thresholds listed above\\], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).\n     3. Previously documented elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP\u002Fcardiac output ratio ≥2 mmHg\u002FL\u002Fmin for upright exercise).\n     4. Elevated H2FPEF score69 (≥5) or HFA-PEFF70 score (≥5).\n\nSuspected HFpEF criteria\n\n1. Age ≥30 years.\n2. Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability)\n3. Signs and\u002For symptoms of HF, NYHA functional class II-IV and all of the following:\n\n   1. Does not meet BNP or NT-proBNP criteria for HFpEF (above)\n   2. No prior HF hospitalization meeting HF criteria (above)\n   3. No previous hemodynamic catheterization documentation of HF (as above)\n\nExclusion Criteria:\n\n* 1\\. Inadequate echo or fluoroscopic images.\n\n  2\\. Neck anatomy unfavorable for jugular venous cannulation\n\n  3\\. Therapy with direct oral anticoagulants without cessation for a period (age, renal function, and agent specific) deemed adequate to normalize coagulation according to local clinical guidelines.\n\n  4\\. Previous or ongoing therapy with warfarin with INR ≥ 1.6 measured day before or of EMB\n\n  5\\. Platelet count \\\u003C 50,000\u002Fml\n\n  6\\. Active bleeding or coagulation disorder\n\n  7\\. Infection or fever\n\n  8\\. Endocarditis\n\n  9\\. Pregnancy\n\n  10\\. Intracardiac thrombus\n\n  11\\. RV Aneurysm\n\n  12\\. Clinically significant tricuspid, pulmonary or aortic valve stenosis\n\n  13\\. Tricuspid or pulmonary mechanical valve prosthesis\n\n  14\\. Left bundle branch block",true,"ALL","30 Years",{"count":168,"type":169},180,"ESTIMATED","4 Years","OBSERVATIONAL","The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.",[174,175],"Heart Failure","Heart Failure With Preserved Ejection Fraction","2026-04-08",{"date":178,"type":179},"2026-04-09","ACTUAL",{"date":181,"type":179},"2024-11-08",{"date":183,"type":169},"2026-12",{"name":5,"class":6},6]